Free Trial

Cencora (COR) Stock Forecast & Price Target

Cencora logo
$292.52 -0.18 (-0.06%)
Closing price 09/5/2025 03:59 PM Eastern
Extended Trading
$284.82 -7.70 (-2.63%)
As of 09/5/2025 05:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Cencora - Analysts' Recommendations and Stock Price Forecast (2025)

Consensus Rating

Sell
0
Hold
3
Buy
9

Based on 12 Wall Street analysts who have issued ratings for Cencora in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 12 analysts, 3 have given a hold rating, and 9 have given a buy rating for COR.

Consensus Price Target

$311.25
6.40% Upside
According to the 12 analysts' twelve-month price targets for Cencora, the average price target is $311.25. The highest price target for COR is $355.00, while the lowest price target for COR is $275.00. The average price target represents a forecasted upside of 6.40% from the current price of $292.52.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for COR and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cencora and its competitors.

Sign Up
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

COR Analyst Ratings Over Time

TypeCurrent Forecast
9/7/24 to 9/7/25
1 Month Ago
8/8/24 to 8/8/25
3 Months Ago
6/9/24 to 6/9/25
1 Year Ago
9/8/23 to 9/7/24
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
9 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
6 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
1 Hold rating(s)
2 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$311.25$309.83$306.91$258.13
Forecasted Upside6.40% Upside8.54% Upside8.09% Upside9.85% Upside
Consensus RatingModerate BuyModerate BuyModerate BuyModerate Buy

COR Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

COR Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Cencora Stock vs. The Competition

TypeCencoraMedical CompaniesS&P 500
Consensus Rating Score
2.75
2.78
2.53
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside6.40% Upside16,047.34% Upside10.35% Upside
News Sentiment Rating
Very Positive News

See Recent COR News
Positive News
Positive News
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside
Details
8/13/2025Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Stephen Baxter
Stephen Baxter
4 of 5 stars
Boost TargetOverweight$337.00 ➝ $354.00+22.31%
7/16/2025Morgan Stanley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Erin Wright
Erin Wright
5 of 5 stars
Set TargetEqual Weight$313.00 ➝ $330.00+12.00%
6/30/2025Jefferies Financial Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetHold$275.00 ➝ $300.00+0.55%
5/8/2025Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$330.00 ➝ $355.00+23.80%
5/8/2025Robert W. Baird
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$314.00 ➝ $350.00+15.12%
4/29/2025UBS Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetBuy$298.00 ➝ $335.00+16.26%
4/11/2025Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetNeutral$270.00 ➝ $285.00+2.14%
2/6/2025Evercore ISI
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOutperform$270.00 ➝ $280.00+12.80%
1/24/2025JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost TargetOverweight$289.00 ➝ $301.00+21.13%
12/4/2024Mizuho
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageHoldOutperform$280.00+11.98%
11/7/2024Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Boost TargetOverweight$263.00 ➝ $290.00+18.18%
10/7/2024Leerink Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
 Lower TargetOutperform$277.00 ➝ $275.00+25.03%
2/26/2024Leerink Partnrs
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Sunday at 05:57 PM ET.


Should I Buy Cencora Stock? COR Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, September 5, 2025. Please send any questions or comments about these Cencora pros and cons to contact@marketbeat.com.

Cencora
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Cencora, Inc.:

  • Recent analyst upgrades have increased target prices significantly, indicating strong market confidence in Cencora, Inc.'s growth potential.
  • The current stock price is around $354, reflecting a positive trend and investor interest in the company.
  • Insider ownership stands at 10.80%, suggesting that those with the most knowledge about the company have a vested interest in its success.
  • The company has a low payout ratio of 22.63%, indicating that it retains a significant portion of its earnings for reinvestment, which can fuel future growth.
  • Cencora, Inc. has received multiple "Buy" ratings from analysts, with a consensus rating of "Moderate Buy," which may attract more investors looking for solid opportunities.

Cencora
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Cencora, Inc. for these reasons:

  • Insider selling of 34,125 shares worth nearly $10 million in the last ninety days may raise concerns about the company's short-term outlook.
  • The dividend yield is relatively low at 0.7%, which may not attract income-focused investors looking for higher returns.
  • Despite positive analyst ratings, the stock's average target price of $311.25 suggests that there may be limited upside potential from the current price.
  • Market volatility can impact stock performance, and recent fluctuations in the pharmaceutical sector may pose risks to Cencora, Inc.'s stability.
  • With nine analysts rating the stock as "Buy," there is a risk of overvaluation if market sentiment shifts, potentially leading to a price correction.

COR Forecast - Frequently Asked Questions

According to the research reports of 12 Wall Street equities research analysts, the average twelve-month stock price forecast for Cencora is $311.25, with a high forecast of $355.00 and a low forecast of $275.00.

12 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Cencora in the last twelve months. There are currently 3 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" COR shares.

According to analysts, Cencora's stock has a predicted upside of 6.40% based on their 12-month stock forecasts.

Cencora has been rated by research analysts at Jefferies Financial Group, Morgan Stanley, and Wells Fargo & Company in the past 90 days.

Analysts like Cencora less than other "medical" companies. The consensus rating score for Cencora is 2.75 while the average consensus rating score for "medical" companies is 2.78. Learn more on how COR compares to other companies.


This page (NYSE:COR) was last updated on 9/7/2025 by MarketBeat.com Staff
From Our Partners